Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233207 · ClinicalTrials.gov registry record · Phase 2
IC14 Antibodies to Treat Individuals With Acute Lung Injury
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00233207 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 13 participants.
The verdict
NCT00233207, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a phase II, randomized, double-blind, placebo-controlled, safety and efficacy study of a recombinant chimeric monoclonal antibody against CD14 (IC14) in hospitalized patients with acute lung injury (ALI).
Interventions
- DRUG IC14
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233207
The ClinicalTrials.gov registry entry for NCT00233207 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IC14 is the first listed.
NCT00233207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233207 about?
NCT00233207 is a clinical study titled "IC14 Antibodies to Treat Individuals With Acute Lung Injury". This is a phase II, randomized, double-blind, placebo-controlled, safety and efficacy study of a recombinant chimeric monoclonal antibody against CD14 (IC14) in hospitalized patients with acute lung injury (ALI).
What is the current status of trial NCT00233207?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2005-09. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00233207?
The interventions under investigation include: IC14 (DRUG).
Who is sponsoring clinical trial NCT00233207?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.